Theseus Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for THE-630, a Pan-Variant KIT Inhibitor in Development for the Treatment of Gastrointestinal Stromal Tumors (GIST)
CAMBRIDGE, Mass., Nov. 1, 2021 -- (Healthcare Sales & Marketing Network) --Theseus Pharmaceuticals, Inc. ("Theseus"), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercial... Biopharmaceuticals, Oncology, FDA Theseus Pharmaceuticals, targeted oncology, gastrointestinal stromal tumors (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 1, 2021 Category: Pharmaceuticals Source Type: news

Telehealth Took Off During the Pandemic. Now, Battles Over State Lines and Licensing Threaten Patients ’ Options
Televisits for medical care took off during the worst days of the pandemic, quickly becoming commonplace. Throughout, it’s probably seemed like it doesn’t matter what state the provider of these telehealth services is located. But that’s only because most states, along with the U.S. Centers for Medicare & Medicaid Services, temporarily waived rules requiring licensed clinicians to hold a valid license in the state where their patient is located. Now states are rolling back many of those pandemic workarounds—meaning the ability to conduct certain virtual appointments may be nearing an end. Johns ...
Source: TIME: Health - August 26, 2021 Category: Consumer Health News Authors: Julie Appleby / Kaiser Health News Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

FDA approves ripretinib for advanced gastrointestinal stromal tumor
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors
Founded by pioneers of targeted oncology, Theseus is developing best-in-class TKIs to overcome cancer resistance Presentation at AACR highlights THE-630, the Company's next-generation inhibitor for KIT-mutant gastrointestinal stromal tumors (GIST) BO... Biopharmaceuticals, Oncology, Venture Capital Theseus Pharmaceuticals, targeted oncology (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 13, 2021 Category: Pharmaceuticals Source Type: news

Near-Infrared Imaging for Tumors Deep in Tissue, Such as GISTs Near-Infrared Imaging for Tumors Deep in Tissue, Such as GISTs
Near-infrared hyperspectral imaging combined with machine learning may hold promise for identifying deep-tissue gastrointestinal stromal tumors (GISTs).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 18, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Chatter between cell populations drives progression of gastrointestinal tumors
(University of California - San Diego) Researchers at University of California San Diego School of Medicine identified new therapeutic targets for gastrointestinal stromal tumors (GISTs) that could lead to new treatment options for patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 18, 2021 Category: International Medicine & Public Health Source Type: news

Deep Vision: Near-infrared imaging and machine learning can identify hidden tumors
(Tokyo University of Science) Gastrointestinal stromal tumors are tumors of the digestive tract that grow underneath the mucus layer covering our organs. Because they are deep inside the tissue, these " submucosal tumors " are difficult to detect and diagnose, even with a biopsy. Now, researchers from Japan have developed a novel minimally invasive and accurate method using infrared imaging and machine learning to distinguish between normal tissue and tumor areas. This technique has a strong potential for widespread clinical use. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 2, 2021 Category: Cancer & Oncology Source Type: news

Survival Rate for Gastrointestinal Stromal Tumors
What Is the Survival Rate for Gastrointestinal Stromal Tumors? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 27, 2021 Category: General Medicine Source Type: news

Genetic testing cost effective for newly diagnosed GIST
(University of California - San Diego) UC San Diego School of Medicine researchers reported that genetic testing is cost-effective and beneficial for newly diagnosed patients with metastatic gastrointestinal stromal tumors (GIST), a rare type of cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 28, 2020 Category: Cancer & Oncology Source Type: news

Blueprint Medicines Announces European Commission Approval of AYVAKYT(R) (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors
CAMBRIDGE, Mass., Sept. 25, 2020 -- (Healthcare Sales & Marketing Network) -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that ... Biopharmaceuticals, Regulatory Blueprint Medicines, AYVAKIT, avapritinib, gastrointestinal stromal tumor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 25, 2020 Category: Pharmaceuticals Source Type: news

Blueprint Medicines Strengthens Leadership with Appointment of Fouad Namouni, M.D., as President, Research and Development
Newly created role to oversee R&D organization and advance precision medicine portfolio vision CAMBRIDGE, Mass., Sept. 1, 2020 -- (Healthcare Sales & Marketing Network) -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company foc... Biopharmaceuticals, Personnel Blueprint Medicines, AYVAKIT, avapritinib, gastrointestinal stromal tumor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 1, 2020 Category: Pharmaceuticals Source Type: news

Ripretinib Extends Survival When All Else Fails in Advanced GIST Ripretinib Extends Survival When All Else Fails in Advanced GIST
Treatment with oral ripretinib significantly prolonged survival in patients with advanced gastrointestinal stromal tumors (GIST) who did not respond or were intolerant to three other tyrosine-kinase inhibitors in the INVICTUS study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 6, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Three Years of Imatinib May Halve Death Rate in GIST Three Years of Imatinib May Halve Death Rate in GIST
Giving patients with high-risk gastrointestinal stromal tumors imatinib for 3 years rather than 1 year may reduce 10-year mortality by half, say German and Finnish investigators.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 8, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

QINLOCK (Ripretinib), FDA Approved for Treatment of Gastrointestinal Stromal Tumors (GIST), Available at Biologics by McKesson
CARY, N.C., June 4, 2020 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Deciphera Pharmaceuticals as a specialty pharmacy provider for QINLOCKTM (ripretinib) for the treatment of adult patients with advanced gastrointestinal ... (Source: McKesson News)
Source: McKesson News - June 4, 2020 Category: Information Technology Source Type: news

Qinlock (Ripretinib) Approved as Fourth-Line Treatment for GIST
MONDAY, May 18, 2020 -- The U.S. Food and Drug Administration approved Qinlock (ripretinib) tablets as a fourth-line treatment for adults with advanced gastrointestinal stromal tumors (GISTs), the agency announced Friday. The approval follows four... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 18, 2020 Category: General Medicine Source Type: news

FDA Approves Ripretinib for Advanced GISTs FDA Approves Ripretinib for Advanced GISTs
The oral therapy is the first-ever drug specifically approved as a fourth-line treatment for advanced gastrointestinal stromal tumors (GISTs).FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - May 18, 2020 Category: Drugs & Pharmacology Tags: Hematology-Oncology News Source Type: news

FDA approves ripretinib for advanced gastrointestinal stromal tumor
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 15, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors
FDA has approved Qinlock (ripretinib) tablets as the first new drug specifically approved as a fourth-line treatment for advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 15, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Blueprint Medicines Receives Complete Response Letter from FDA for Avapritinib New Drug Application for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
CAMBRIDGE, Mass., May 15, 2020 -- (Healthcare Sales & Marketing Network) -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that th... Biopharmaceuticals, FDA Blueprint Medicines, AYVAKIT, avapritinib, gastrointestinal stromal tumor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 15, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves Ripretinib Tablets for Advanced Gastrointestinal Stromal Tumor
Ripretinib is now indicated for adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with 3 or more kinase inhibitor therapies. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Approves Qinlock (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
WALTHAM, Mass.--(BUSINESS WIRE)--May 15, 2020-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the U.S. Food and Drug Administration (FDA) has approved Qinlock™ (ripretinib) for the treatment of adult patients with advanced... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 15, 2020 Category: Drugs & Pharmacology Source Type: news

Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor
VOYAGER did not meet the primary endpoint of an improvement in progression-free survival for avapritinib versus regorafenib in patients with third- or fourth-line GIST Plan to continue to prioritize portfolio opportunities in systemic mastocytosis and R... Biopharmaceuticals, Oncology Blueprint Medicines, avapritinib, gastrointestinal stromal tumor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 28, 2020 Category: Pharmaceuticals Source Type: news

FDA Grants Priority Review to Ripretinib for Advanced Gastrointestinal Stromal Tumors
The FDA granted a priority review to Deciphera Pharmaceuticals ’ new drug application for ripretinib to treat patients with advanced gastrointestinal stromal tumors. (Source: CancerNetwork)
Source: CancerNetwork - February 13, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Deciphera Pharmaceuticals Announces U.S. Food And Drug Administration Acceptance Of New Drug Application And Priority Review For Ripretinib In Patients With Advanced Gastrointestinal Stromal Tumors
WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 12, 2020-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its New Drug Application (NDA)... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 12, 2020 Category: Drugs & Pharmacology Source Type: news

Drug Trial Snapshot: AYVAKIT
AYVAKIT is used to treat adult patients with gastrointestinal stromal tumor (GIST) whose disease: is caused by certain abnormal platelet-derived growth factor receptor alpha (PDGFRA) genes and, cannot be surgically removed or, has spread throughout the body (metastatic GIST). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 24, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
The U.S. Food and Drug Administration approved Ayvakit (avapritinib) for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) gastrointestinal stromal tumor (GIST) - a type of tumor that occurs in the gastrointestinal tract, (Source: World Pharma News)
Source: World Pharma News - January 10, 2020 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Ayvakit Approved to Treat GIST With PDGFRA Exon 18 Mutation
FRIDAY, Jan. 10, 2020 -- The kinase inhibitor Ayvakit (avapritinib) has been approved to treat adults with unresectable or metastatic gastrointestinal stromal tumors (GISTs) with a platelet-derived growth factor receptor alpha (PDGFRA) exon 18... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 10, 2020 Category: General Medicine Source Type: news

FDA Approves Avapritinib for Resectable or Metastatic Gastrointestinal Stromal Tumor
The FDA approved avapritinib for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumor harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. (Source: CancerNetwork)
Source: CancerNetwork - January 10, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

FDA Approves Avapritinib (Ayvakit) for GIST with Mutation FDA Approves Avapritinib (Ayvakit) for GIST with Mutation
The new product is indicated for use in gastrointestinal stromal tumors (GIST) that harbor a mutation, which renders these tumors resistant to standard therapy.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation
On January 9, 2020, FDA approved avapritinib (AYVAKITTM, Blueprint Medicines Corporation) for adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including D842V mutations. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 9, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
FDA approved Ayvakit (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 9, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Ayvakit (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor
CAMBRIDGE, Mass., Jan. 9, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 9, 2020 Category: Drugs & Pharmacology Source Type: news

Deciphera Pharmaceuticals Announces Submission of New Drug Application to U.S. FDA for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 16, 2019-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ripretinib, the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 16, 2019 Category: Drugs & Pharmacology Source Type: news

NIOSH Asking for National Mesothelioma Registry Input
The National Institute for Occupational Safety and Health has begun soliciting public input on the feasibility of establishing a mesothelioma registry. NIOSH is encouraging doctors, nurses, patients, families and patient advocates to provide recommendations on data collection, enrollment, registry maintenance, confidentiality and the overall usefulness of such a tool if enacted. Comments must be received by July 8, 2019. “NIOSH has a strong interest in preventing mesothelioma and helping people with the disease,” according to its outreach effort on Regulations.gov. “Mesothelioma treatments are limited, an...
Source: Asbestos and Mesothelioma News - May 1, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Congress Funds Feasibility Study for Mesothelioma Patient Registry
The National Institute for Occupational Safety and Health will oversee a study in 2019 to determine the feasibility of establishing the first national mesothelioma patient registry. The $100,000 feasibility study was part of the $1.2 million Congress allocated in 2019 to the Centers of Disease Control and Prevention for mesothelioma research. The bulk of the funding goes toward the National Mesothelioma Virtual Bank, which is a biospecimen registry first established in 2006. It is the only federally funded program designed exclusively for the research of mesothelioma, the rare and aggressive cancer caused by asbestos expos...
Source: Asbestos and Mesothelioma News - January 15, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

CHLA participates in novel cancer consortium announced at the Biden Cancer Summit
(Children's Hospital Los Angeles) Former Vice President Joe Biden and Dr. Jill Biden hosted the national Biden Cancer Summit, on Sept. 21, to highlight the urgent need for creating transformative approaches to cancer prevention, research and treatment. One of the new initiatives announced was the formation of a consortium to advance research into effective treatments for patients with a type of cancer called Gastrointestinal Stromal Tumor (GIST) who do not respond to current standard treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 21, 2018 Category: International Medicine & Public Health Source Type: news

Gastrointestinal Stromal Tumors
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 27, 2018 Category: General Medicine Source Type: news

Gastrointestinal Stromal Tumors in Children
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - November 8, 2017 Category: General Medicine Source Type: news

GIST tumors linked to NF1 mutations, genetic testing needed
(University of California - San Diego) Researchers at UC San Diego Moores Cancer Center, with colleagues from Memorial Sloan Kettering Cancer Center and Fox Chase Cancer Center, have determined that a specific region of the small bowel, called the duodenal-jejunal flexure or DJF, shows a high frequency of gastrointestinal stromal tumors (GISTs) with mutations of the NF1 gene. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 18, 2017 Category: International Medicine & Public Health Source Type: news

Activity of PD-1 Inhibitor Limited in Soft-Tissue Sarcomas
Treatment with the PD-1 inhibitor pembrolizumab plus metronomic cyclophosphamide had limited activity in patients with soft-tissue sarcomas and gastrointestinal stromal tumors. (Source: CancerNetwork)
Source: CancerNetwork - July 11, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: News Sarcoma Source Type: news

KIT Mutations Linked to Imatinib Response in GIST KIT Mutations Linked to Imatinib Response in GIST
Different KIT mutations have various associations with the response of gastrointestinal stromal tumors (GISTs) to adjuvant imatinib, according to results from a Scandinavian Sarcoma Group multicenter trial.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 3, 2017 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Immunicum begins enrolment in Phase I/II trial of INTUVAX to treat GIST
Swedish-based biopharmaceutical company Immunicum has commenced enrolment in the Phase I/II clinical trial of INTUVAX for the treatment of patients with gastrointestinal stromal tumour (GIST). (Source: Drug Development Technology)
Source: Drug Development Technology - March 8, 2017 Category: Pharmaceuticals Source Type: news

Imatinib of Long-Term Help in Some Patients With GI Stromal Tumors Imatinib of Long-Term Help in Some Patients With GI Stromal Tumors
A substantial minority of patients with advanced gastrointestinal stromal tumors (GIST) treated with imatinib mesylate show long-term survival, according to a trial analysis presenting new molecular data.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - February 21, 2017 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Study shows strong long-term survival rates for patients with GIST
Nearly one in four patients with incurable gastrointestinal stromal tumors (GIST) treated with Gleevec will survive 10 years, a new report outlines. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 20, 2017 Category: Science Source Type: news

SWOG study shows strong long-term survival rates for patients with GIST
(SWOG) Researchers show that nearly one in four patients with incurable gastrointestinal stromal tumors (GIST) treated with Gleevec will survive 10 years. Results are published in JAMA Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 20, 2017 Category: Global & Universal Source Type: news

Clinical Insights Into Gastrointestinal Stromal Tumours Clinical Insights Into Gastrointestinal Stromal Tumours
This study examined the treatment outcomes of GISTs, highlighting some of the diagnostic and therapeutic challenges.Frontline Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 13, 2017 Category: Consumer Health News Tags: Radiology Journal Article Source Type: news

Surgery May Be Preferable in Young Adults With GI Stromal Tumors Surgery May Be Preferable in Young Adults With GI Stromal Tumors
Young adults with gastrointestinal stromal tumors (GISTs) appear to fare best after undergoing operative treatment, according to a retrospective study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 26, 2017 Category: Surgery Tags: General Surgery News Source Type: news

Small intestine GIST associated with better prognosis in younger patients
Gastrointestinal stromal tumors (GIST) are tumors that arise is the wall of the digestive tract, and most often occur in the stomach or small intestine. Though more common in later in life, GISTs can occur in adolescents and young adults (AYA) under 40 years old as well. Researchers report findings from the first population-based analysis of AYA patients with GIST. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 18, 2017 Category: Science Source Type: news

Small intestine GIST associated with better prognosis in younger patients
(University of California - San Diego) Gastrointestinal stromal tumors (GIST) are tumors that arise is the wall of the digestive tract, and most often occur in the stomach or small intestine. Though more common in later in life, GISTs can occur in adolescents and young adults (AYA) under 40 years old as well. Researchers at the University of California San Diego School of Medicine report findings from the first population-based analysis of AYA patients with GIST. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 18, 2017 Category: Global & Universal Source Type: news

Columbia, NewYork-Presbyterian and non-profit Life Raft Group form cancer partnership
(Columbia University Medical Center) Collaboration will investigate the efficacy of a system biology approach to identifying treatment options for patients with advanced gastrointestinal stromal tumors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 11, 2017 Category: Global & Universal Source Type: news